The addition of adjuvant nivolumab to standard-of-care radiotherapy and cisplatin improved survival for patients with locally ...

Chemotherapy regimen shows potential to improve survival and reduce need for surgery in patients with muscle-invasive bladder ...

Overall survival at two years was 82.2% in the durvalumab group and 75.2% in the comparator group. Durvalumab (brand name ...

Cisplatin is widely used as part of first-line therapy for many cancer types, including bladder, ovarian, cervical, testicular, lung and breast cancer, as well as sarcomas, lymphomas and leukemias.

Cisplatin, a widely used anticancer drug, has been used in combination therapies but its use is limited by severe side effects, including renal toxicity, highlighting the need for safer and more ...

Post-operative nivolumab significantly improved disease-free survival in resected locally advanced head and neck cancer, ...

Neoadjuvant chemotherapy followed by transoral robotic surgery (NECTORS) and neck dissection led to better survival outcomes ...

A major clinical trial, led by the University of Sheffield, has revealed survival rates for patients with operable bladder ...

Durvalumab did not improve outcomes compared with cetuximab in patients with head and neck squamous cell carcinoma who are ...

PEDMARQSI ® (anhydrous sodium thiosulfate) is the first and only treatment available within NHS England and Wales for the prevention of cisplatin-induced ototoxicity (hearing loss) in children ...